Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Saturday
May 07
16:55 - 17:55
Poster Station 2
08: Advances in radiotherapy planning & techniques
Madalyne Day, Switzerland
Poster Discussion
RTT
To re-opt or not to re-opt: a study on the need for online plan adaptation for prostate cancer
Lisa Verweij, The Netherlands
PD-0331

Abstract

To re-opt or not to re-opt: a study on the need for online plan adaptation for prostate cancer
Authors:

Lisa Verweij1, Shyama U. Tetar1, Omar Bohoudi1, Berend J. Slotman1, Anna M.E. Bruynzeel1, Frank J. Lagerwaard1, Miguel A. Palacios1

1Amsterdam UMC, VUmc location, de Boelelaan 1117, 1081 HV, Department of Radiation Oncology, Amsterdam, The Netherlands

Show Affiliations
Purpose or Objective

Online adaptive MR-guided radiotherapy (MRgRT) involves re-contouring and plan re-optimization prior to each fraction to ensure adequate target coverage and maximal organ-at-risk sparing. Additionally, in general adaptive MRgRT is delivered using only minimal CTV to PTV safety margins. This online procedure is time-consuming and may not always be needed, e.g. when the interfractional anatomical changes are limited. In this study, we evaluated outcomes of target coverage and OAR doses when plan re-optimization was not performed using CTV to PTV margins of 3mm and 5 mm, respectively.

Material and Methods

Ten patients with localized prostate cancer previously treated with MRgRT in 36.25 Gy in 5 fractions were included in this study. The CTV was partitioned in a CTVPR (prostate) and a CTVSV (seminal vesicles) by an experienced radiation oncologist. This was performed for all six MR-scans available during MRgRT, the simulation scan and high-resolution scans of fraction 1-5. All CTVs were expanded with a 3 and 5 mm margin, respectively, generating a PTVPR_3mm, PTVPR_5mm, PTVSV_3mm and PTVSV_5mm (Figure 1). Baseline plans were generated for both the 3- and 5mm margin plans. After alignment of the CTV, these baseline plans were recalculated for the anatomy of the day on each pre-treatment MRI (non-reoptimized plans). Target dosimetry (for both the 3- and 5mm plans) was evaluated by determining coverage of CTVPR and CTVSV by the 95% isodose line for each of the 50 fractions. A CTV coverage of V95% > 93% was considered as adequate. Doses to rectum and bladder were determined to evaluate the effect of applying varying PTV margins to relevant OARs.


Results

The 3mm CTV to PTV margin plans had adequate coverage of the prostate and seminal vesicles in only 76% and 46%, respectively of all investigated 50 plans (Table 1). Increasing the CTV to PTV margins to 5mm ensured adequate coverage of the prostate in all but one fractions, however seminal vesicles coverage remained inadequate in 24% of plans. The improved coverage using the 5mm margins came at a cost of OAR doses. The bladder V100% and V90% increased on average 0.61cc and 3.33cc, respectively (p<0.01). Similarly, the rectum V100% and V90% increased 0.25cc and 1.77cc, respectively (p<0.01) in comparison to the 3mm plans.

Conclusion

Without plan re-optimization and use of a 3 mm PTV margin, coverage of the CTV’s of the prostate and seminal vesicles was inadequate in about a quarter and half of the fractions, respectively. Increasing the margins to 5mm corrected prostate coverage at the expense of a higher OAR dose. Also with 5mm margins, coverage of seminal vesicles was inadequate in approximately one quarter of plans. These results underscore the need for routine online plan adaptation, particularly when using 3mm margins. Use of implanted gold markers in the prostate for CTV alignment on conventional linacs may be insufficient in intermediate- and high-risk patients with SV involvement.